| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| S C Leiser, A L Pehrson, P J Robichaud, C Sanche. Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats. British journal of pharmacology. vol 171. issue 18. 2015-05-26. PMID:24846338. |
vortioxetine is a 5-ht3 , 5-ht7 , and 5-ht1d receptor antagonist, 5-ht1b partial agonist, 5-ht1a agonist, and 5-ht transporter inhibitor. |
2015-05-26 |
2023-08-13 |
rat |
| Juan-Juan Qin, Hong-Xia Chen, Nan Zhao, Li Yuan, You-Zhi Zhang, Ri-Fang Yang, Li-Ming Zhang, Yun-Feng L. The role of activation of the 5-HT1A receptor and adenylate cyclase in the antidepressant-like effect of YL-0919, a dual 5-HT1A agonist and selective serotonin reuptake inhibitor. Neuroscience letters. vol 582. 2015-05-26. PMID:25220701. |
the role of activation of the 5-ht1a receptor and adenylate cyclase in the antidepressant-like effect of yl-0919, a dual 5-ht1a agonist and selective serotonin reuptake inhibitor. |
2015-05-26 |
2023-08-13 |
mouse |
| Juan-Juan Qin, Hong-Xia Chen, Nan Zhao, Li Yuan, You-Zhi Zhang, Ri-Fang Yang, Li-Ming Zhang, Yun-Feng L. The role of activation of the 5-HT1A receptor and adenylate cyclase in the antidepressant-like effect of YL-0919, a dual 5-HT1A agonist and selective serotonin reuptake inhibitor. Neuroscience letters. vol 582. 2015-05-26. PMID:25220701. |
this study aimed to explore the possible mechanisms underlying the antidepressant-like effect of yl-0919, a novel antidepressant candidate with dual activity as a 5-ht1a receptor agonist and a selective serotonin reuptake inhibitor. |
2015-05-26 |
2023-08-13 |
mouse |
| Maria J Ramirez, Mitchell K P Lai, Rosa M Tordera, Paul T Franci. Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status. Drugs. vol 74. issue 7. 2015-05-25. PMID:24802806. |
based on preclinical studies, certain serotonin (5-ht) receptor ligands have been suggested to have the ability to modify or improve memory/cognition, specifically 5-ht receptors acting at 5-ht1a, 5-ht4 and 5-ht6 receptors. |
2015-05-25 |
2023-08-13 |
Not clear |
| Masayoshi Mori, Yusuke Murata, Asami Matsuo, Tomoyo Takemoto, Kazunori Min. Chronic Treatment with the 5-HT1A Receptor Partial Agonist Tandospirone Increases Hippocampal Neurogenesis. Neurology and therapy. vol 3. issue 1. 2015-05-22. PMID:26000223. |
the present study aimed to elucidate whether or not 5-hydroxytryptamine 1a (5-ht1a) receptor partial agonists have a potential therapeutic effect for the treatment of depressive and anxiety disorders, from the standpoint of neurogenesis. |
2015-05-22 |
2023-08-13 |
human |
| Philip D Harve. The clinical utility of lurasidone in schizophrenia: patient considerations. Neuropsychiatric disease and treatment. vol 11. 2015-05-21. PMID:25995636. |
in addition to full antagonist activity at the dopamine d2 (ki, 1 nm) and serotonin 5-ht2a (ki, 0.5 nm) receptors, the pharmacodynamic profile of lurasidone is notable for its high affinity for serotonin 5-ht7 receptors (0.5 nm) and its partial agonist activity at 5-ht1a receptors (ki, 6.4 nm). |
2015-05-21 |
2023-08-13 |
Not clear |
| Noriko Yoshimi, Yuko Fujita, Yuta Ohgi, Takashi Futamura, Tetsuro Kikuchi, Kenji Hashimot. Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors. Pharmacology, biochemistry, and behavior. vol 124. 2015-05-19. PMID:24955861. |
effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-ht1a receptors. |
2015-05-19 |
2023-08-13 |
mouse |
| Rui Zhao, Weijian Lu, Xing Fang, Lin Guo, Zhi Yang, Na Ye, Jiahao Zhao, Zhili Liu, Jia Jia, Longtai Zheng, Bin Zhao, Ao Zhang, Xuechu Zhe. (6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease. Pharmacology, biochemistry, and behavior. vol 124. 2015-05-19. PMID:24955866. |
(6ar)-11-amino-n-propyl-noraporphine, a new dopamine d2 and serotonin 5-ht1a dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-ohda-lesioned rat model of parkinson's disease. |
2015-05-19 |
2023-08-13 |
rat |
| Emily K Stephens, Daniel Avesar, Allan T Gulledg. Activity-dependent serotonergic excitation of callosal projection neurons in the mouse prefrontal cortex. Frontiers in neural circuits. vol 8. 2015-05-15. PMID:25206322. |
layer 5 pyramidal neurons (l5pns) in the mouse prefrontal cortex respond to serotonin (5-ht) according to their long-distance axonal projections; 5-ht1a (1a) receptors mediate inhibitory responses in corticopontine (cpn) l5pns, while 5-ht2a (2a) receptors can enhance action potential (ap) output in callosal/commissural (com) l5pns, either directly (in "com-excited" neurons), or following brief 1a-mediated inhibition (in "com-biphasic" neurons). |
2015-05-15 |
2023-08-13 |
mouse |
| Mirella Nardo, Plinio C Casarotto, Felipe V Gomes, Francisco S Guimarãe. Cannabidiol reverses the mCPP-induced increase in marble-burying behavior. Fundamental & clinical pharmacology. vol 28. issue 5. 2015-05-14. PMID:24118015. |
meta-chloro-phenyl-piperazine (mcpp) is a nonspecific serotonergic agonist (acting mainly at 5ht1a, 5ht2c and 5ht1d receptors) reported to increase symptoms in ocd patients and block the anticompulsive-like effect of serotonin reuptake inhibitors (sris) in animal models. |
2015-05-14 |
2023-08-12 |
Not clear |
| Ana Paula Pesarico, Tuane Bazanella Sampaio, Eluza Curte Stangherlin, Anderson C Mantovani, Gilson Zeni, Cristina Wayne Nogueir. The antidepressant-like effect of 7-fluoro-1,3-diphenylisoquinoline-1-amine in the mouse forced swimming test is mediated by serotonergic and dopaminergic systems. Progress in neuro-psychopharmacology & biological psychiatry. vol 54. 2015-05-12. PMID:24936772. |
pretreatments with p-chlorophenylalanine (100mg/kg, i.p., an inhibitor of 5-ht synthesis), way100635 (0.1mg/kg, s.c., 5-ht1a antagonist), ondansetron (1mg/kg, i.p., a 5-ht3 receptor antagonist), haloperidol (0.2mg/kg, i.p., a non-selective d2 receptor antagonist) and sch23390 (0.05mg/kg, s.c., a d1 receptor antagonist) were effective to block the antidepressant-like effect of fdpi at a dose of 1mg/kg in the fst. |
2015-05-12 |
2023-08-13 |
mouse |
| Karly P Garnock-Jone. Vortioxetine: a review of its use in major depressive disorder. CNS drugs. vol 28. issue 9. 2015-05-12. PMID:25145538. |
vortioxetine (brintellix(®)) is a serotonin (5-ht) transporter inhibitor that also acts on several 5-ht receptors, such as the 5-ht3 and 5-ht1a receptors. |
2015-05-12 |
2023-08-13 |
Not clear |
| Jae Yong Choi, Minkyung Lee, Tae Joo Jeon, Soo-Hee Choi, Ye Ji Choi, Yu Kyung Lee, Jae-Jin Kim, Young Hoon Ry. Determination of optimal acquisition time of [(18)F]FCWAY PET for imaging serotonin 1A receptors in the healthy male subjects. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine. vol 89. 2015-05-11. PMID:24631746. |
the purpose of this research is to find optimal acquisition time point of [(18)f]fcway pet for the assessment of serotonin 1a receptor (5-ht1a) density. |
2015-05-11 |
2023-08-12 |
human |
| Dejan Nikolić, Jinghu Li, Richard B van Breeme. Metabolism of Nω -methylserotonin, a serotonergic constituent of black cohosh (Cimicifuga racemosa, L. (Nutt.)), by human liver microsomes. Biomedical chromatography : BMC. vol 28. issue 12. 2015-05-11. PMID:24817649. |
although not estrogenic, nω -methylserotonin has been identified in black cohosh as a potent agonist of serotonin 5-ht1a and 5-ht7 receptors. |
2015-05-11 |
2023-08-13 |
human |
| David J Hellerstein, Joseph Flaxe. Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy. Core evidence. vol 10. 2015-05-06. PMID:25945081. |
vilazodone, introduced in the us in 2011, has been described as the first member of the serotonin partial agonist-reuptake inhibitor (spari) class of medications, combining serotonin-reuptake inhibition with 5-ht1a partial agonism. |
2015-05-06 |
2023-08-13 |
Not clear |
| Grażyna Żydek, Elżbieta Brzezińska, Andrzej Stańczak, Wiesława Lewgow. Application of chromatographic data in QSAR Studies of 3-[ω-(4-Arylpiperazin-1-yl)alkyl]pyrimido[5,4-c]quinolin-4(3H)-one derivatives as 5-HT1A receptor ligands. Journal of chromatographic science. vol 52. issue 7. 2015-04-21. PMID:23804019. |
the activity of several 3-[ω-(4-arylpiperazin-1-yl)alkyl]pyrimido[5,4-c]quinolin-4(3h)-ones (lcaps) with well-defined serotonin 1a (5-ht1a) receptor affinity was described by using chromatographic and calculated physicochemical parameters in quantitative structure-activity relationship analysis. |
2015-04-21 |
2023-08-12 |
Not clear |
| Mauro Giovanni Carta, Andrea Norcini Pala, Gabriele Finco, Mario Musu, Maria Francesca Mor. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option? Clinical practice and epidemiology in mental health : CP & EMH. vol 11. 2015-04-20. PMID:25893002. |
mechanism of action : vortioxetine has 5-ht3, 5-ht7 and 5-ht1d antagonists, 5-ht1b partial agonist and a 5-ht1a agonist and serotonin transporter inhibitor property. |
2015-04-20 |
2023-08-13 |
Not clear |
| Maria Cano-Colino, Rita Almeida, David Gomez-Cabrero, Francesc Artigas, Albert Compt. Serotonin regulates performance nonmonotonically in a spatial working memory network. Cerebral cortex (New York, N.Y. : 1991). vol 24. issue 9. 2015-04-13. PMID:23629582. |
we found that 5-ht modulates network's swm performance nonmonotonically via 5-ht1a and 5-ht2a receptors, following an inverted u-shape. |
2015-04-13 |
2023-08-12 |
Not clear |
| Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Chi-Un Pa. Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action. Psychiatry investigation. vol 12. issue 2. 2015-04-13. PMID:25866514. |
vilazodone is an antidepressant with novel mechanism of action because its chemical structure is unrelated to conventional antidepressant, and it has a selective serotonin (5-ht) reuptake inhibitor and 5-ht1a receptor partial agonist profile. |
2015-04-13 |
2023-08-13 |
Not clear |
| Valentina Mosienko, Susann Matthes, Natalie Hirth, Daniel Beis, Michael Flinders, Michael Bader, Anita C Hansson, Natalia Alenin. Adaptive changes in serotonin metabolism preserve normal behavior in mice with reduced TPH2 activity. Neuropharmacology. vol 85. 2015-03-30. PMID:24863038. |
in contrast, 5-ht1a autoreceptor density and g-protein coupling were not changed in mice with gradual decrease in central serotonin. |
2015-03-30 |
2023-08-13 |
mouse |